This laboratory recently discovered that primary B-lymphocytes can be programmed for the synthesis and delivery of short, non-coding RNAs in vitro and in vivo. In this revised R21 application we intend to rapidly adapt this new concept and test it in the context of tumor therapy to limit or control cancer cell growth and metastasis. miRNA "signatures" have been identified in both hematological malignancies and solid tumors, distinguishing tumor cells from normal cells. In some instances miRNAs are associated with the prognosis and the progression of cancer. This can happen because of one of two conditions: loss of suppressor miRNAs or overexpression of oncogenic miRNAs. miRNA-based therapy can then be geared at either restore the loss of a particular miRNA or suppress an oncogenic miRNA, respectively. The present proposal aims at gathering first line proof-of-concept that primary B lymphocytes synthesizing and secreting short, non-coding miRNAs can be used to treat cancer in vivo, a new form of therapy that we have termed immunogenomic therapy to typify its hybrid (genomic and immunological) nature. The following three Aims are proposed: (1) Engineer and characterize therapeutic plasmid vectors for miRNA replacement or inhibition;(2) miRNA inhibition: Targeting miR-155 in B leukemic cells;and (3) miRNA replacement: Restoring miR-335 in metastatic breast cancer cells. It is hoped that the work proposed in this high risk/high pay off revised proposal will provide us with the answers needed for a proof-of-principle validation of the new idea. We anticipate that success in obtaining proof-of-concept validation for immunogenomic therapy will open new horizons for the treatment of cancer and metastases.

Public Health Relevance

This new R21 application is based on the new finding by this laboratory that primary B-lymphocytes can be programmed to the synthesis and delivery of short, non-ding RNAs. The goal of this application is to gather proof-of-principle evidence that this new approach can be adapted to the treatment of cancer.

Agency
National Institute of Health (NIH)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA178674-01A1
Application #
8692305
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Yovandich, Jason L
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92093